Replimune Group (NASDAQ:REPL) Receives Buy Rating from HC Wainwright

Replimune Group (NASDAQ:REPL - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $17.00 price objective on the stock. HC Wainwright's target price suggests a potential upside of 39.46% from the stock's previous close.

REPL has been the subject of a number of other reports. Roth Capital raised shares of Replimune Group to a "strong-buy" rating in a research report on Tuesday, August 27th. Roth Mkm assumed coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a "buy" rating and a $17.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, September 24th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $16.80.

Replimune Group Stock Down 2.5 %

Shares of NASDAQ REPL traded down $0.31 during mid-day trading on Tuesday, reaching $12.19. The company had a trading volume of 460,407 shares, compared to its average volume of 1,040,354. The stock has a fifty day moving average of $11.42 and a two-hundred day moving average of $9.49. The company has a debt-to-equity ratio of 0.16, a quick ratio of 13.46 and a current ratio of 13.46. The company has a market capitalization of $832.82 million, a price-to-earnings ratio of -3.73 and a beta of 1.19. Replimune Group has a 12-month low of $4.92 and a 12-month high of $12.97.

Insider Transactions at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of the firm's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the sale, the chief financial officer now owns 101,057 shares in the company, valued at approximately $1,028,760.26. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 8.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently modified their holdings of REPL. Nisa Investment Advisors LLC boosted its stake in Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company's stock worth $45,000 after buying an additional 4,946 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in shares of Replimune Group in the 2nd quarter valued at $57,000. Arizona State Retirement System acquired a new stake in shares of Replimune Group in the 2nd quarter valued at $108,000. Quest Partners LLC boosted its stake in shares of Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company's stock valued at $122,000 after purchasing an additional 3,150 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Replimune Group in the 1st quarter valued at $140,000. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.